Specialty Pharmacy Services
Sorafenib (Nexavar)
Oral Tablet · Twice Daily · Without Food
Sorafenib (Nexavar) is a targeted therapy used to treat certain cancers of the liver, kidney, and thyroid. Accord Specialty Pharmacy provides sorafenib with prior authorization support, Nexavar copay card enrollment, and doorstep delivery.
Drug at a Glance
- Drug Class Multikinase Inhibitor (Anti-angiogenic / Anti-proliferative)
- Generic Name Sorafenib
- Brand Name Nexavar®
- Route Oral tablet, twice daily (without food)
- Manufacturer Bayer (brand Nexavar) / multiple generics
Clinically Reviewed By · Accord Clinical Team, PharmD, RPh
Sorafenib (Nexavar) at a Glance
| Feature | Sorafenib (Nexavar) |
|---|---|
| Generic Name | Sorafenib |
| Brand Name | Nexavar® |
| Drug Class | Multikinase Inhibitor |
| FDA Approved For | Hepatocellular carcinoma, renal cell carcinoma, differentiated thyroid carcinoma |
| FDA Approved (Year) | 2005 |
| Dosage Form | Oral tablet, twice daily, without food (1 hour before or 2 hours after a meal) |
| Available Generic | Yes |
| Specialty Pharmacy Required | Often required by insurance |
| Prior Authorization | Frequently required |
| Copay Assistance Available | Yes, for eligible commercially insured patients |
| Home Delivery | Available through Accord Specialty Pharmacy |
FDA-Approved Uses
What Sorafenib (Nexavar) Is Used For
Hepatocellular Carcinoma
HCC — UNRESECTABLEHepatocellular carcinoma is the most common form of liver cancer. When HCC cannot be surgically removed due to its size, location, or extent, it is classified as unresectable. Sorafenib is approved for unresectable HCC and has been shown to slow disease progression, typically in patients with preserved liver function.1,2
- Unresectable hepatocellular carcinoma
- Patients with preserved liver function (Child-Pugh A)
Renal Cell Carcinoma
RCC — ADVANCEDRenal cell carcinoma is the most common type of kidney cancer in adults. Sorafenib is approved for advanced RCC that has spread beyond the kidney and is not amenable to surgery alone, including both patients who have received prior treatment and those who have not.2,3
- Advanced renal cell carcinoma
- Prior-treated and treatment-naive settings
Differentiated Thyroid Carcinoma
DTC — RADIOIODINE-REFRACTORYDifferentiated thyroid carcinoma includes the most common subtypes of thyroid cancer — papillary and follicular. Sorafenib is approved for locally recurrent or metastatic DTC that is no longer responding to radioactive iodine treatment, the standard initial approach for many thyroid cancers.2
- Locally recurrent or metastatic DTC
- Radioactive iodine-refractory disease
Your oncologist is the right person to determine which indication applies to your diagnosis and how sorafenib fits into your treatment plan. Learn more about liver cancer treatment from the National Cancer Institute ↗, or read about Oncology specialty pharmacy services →
What Is Sorafenib (Nexavar)?
Sorafenib (Nexavar) is a targeted therapy that disrupts tumor growth through two distinct pathways: it cuts off the tumor's blood supply by blocking signals that trigger new blood vessel formation, and it simultaneously interferes with proteins inside cancer cells that drive their growth and survival. This dual mechanism — anti-angiogenic and anti-proliferative — is what makes sorafenib effective across multiple cancer types.2
Sorafenib is a multikinase inhibitor, meaning it blocks multiple kinase proteins at once. The kinases sorafenib targets include those involved in tumor cell signaling (such as RAF kinases) and those involved in the formation of new blood vessels that feed tumors (such as VEGFR and PDGFR).2 By acting on several pathways simultaneously, sorafenib works to slow tumor growth and limit the cancer's ability to expand and recruit its own blood supply.
Sorafenib is taken as a tablet twice daily and must be taken without food — either one hour before or two hours after a meal. High-fat meals in particular can significantly reduce absorption.2 Accord manages the coordination between your oncologist, your insurance plan, and the assistance programs that help make treatment accessible. Learn how Accord supports patients →
Sorafenib Side Effects and What to Watch For
Like all specialty oncology medications, sorafenib can cause side effects. Your oncologist will review what to watch for before you begin treatment, and regular monitoring is an important part of therapy.
Among the most distinctive sorafenib side effects is hand-foot skin reaction (HFSR) — redness, swelling, pain, blistering, or peeling on the palms of the hands or the soles of the feet.2 This is one of the more characteristic reactions associated with sorafenib and requires active management. Most patients can continue treatment with supportive measures and dose adjustments when needed. Report early signs to your care team promptly. If anything else concerns you while taking sorafenib, call Accord's pharmacy team at 1-855-222-6730.
Frequently Reported2
- Fatigue
- Diarrhea and abdominal pain
- Rash
- Hair thinning or loss
- Weight loss and reduced appetite
- Nausea
- High blood pressure (hypertension)
- Infection
Hand-Foot Skin Reaction2
- Redness, swelling, pain, blistering, or peeling on the palms or soles of the feet — report early signs to your care team
- Moisturizing regularly and avoiding pressure on affected areas can help manage symptoms
- Dose adjustments may be needed if HFSR becomes severe — do not stop sorafenib without talking to your oncologist
- Blood pressure monitoring is required throughout treatment — hypertension is common
Report to Your Care Team Promptly2
- Bleeding or hemorrhage: sorafenib increases the risk of bleeding; report unusual bruising, blood in stool or urine, or coughing up blood
- Blood thinner interaction: taking sorafenib with warfarin may increase the risk of bleeding or affect INR test results — tell your oncologist and our pharmacy team if you take warfarin or any other blood thinner
- Cardiovascular events: myocardial ischemia and QT prolongation have been reported; discuss your cardiac history before starting treatment
- Liver toxicity: sorafenib-induced hepatotoxicity, distinct from underlying disease, has been reported — liver function is monitored during treatment
Prior Authorization for Sorafenib (Nexavar)
Most insurance plans require prior authorization before covering sorafenib. Prior authorization is a process where your oncologist submits clinical documentation to your insurance plan confirming that sorafenib is medically necessary for your condition. For an oncology specialty medication, this typically includes documentation of your diagnosis, stage of disease, and the clinical basis for the treatment choice.
When Accord receives your referral, we contact your oncologist's office to gather what your insurance plan requires, submit the prior authorization request, and follow up proactively until a decision is reached. If your plan issues a denial, we work alongside your oncologist to build a formal appeal with the additional documentation needed to support your case. Information for prescribers →
Prior Authorization Process
Documentation
We request clinical records, diagnosis, and stage documentation from your oncologist
PA Submission
Prior authorization submitted to your insurance plan with full clinical documentation
Plan Decision
Approval issued, or denial received — timelines vary by payer
Appeal if Denied
We build a formal appeal with your oncologist to support your case
Note on appeals: A denial is not necessarily final. Many initially denied requests for sorafenib are approved on formal appeal. Our team manages this process alongside your oncologist at no additional burden to your care team.
Nexavar Copay Card & Sorafenib Financial Assistance
Sorafenib cost at list price is substantial, but the Nexavar copay card and patient assistance programs can bring costs down significantly — in some cases to $0 per month. Our team identifies every program you qualify for before your first fill.
Commercially Insured — Brand
Bayer Access Services Co-Pay Program
$0 per month for eligible patients (up to $25,000/year)
Eligible commercially insured patients prescribed Nexavar may pay $0 per fill with no monthly maximum, up to $25,000 per calendar year. Not available for Medicare, Medicaid, TRICARE, or other government insurance. Call 1-800-288-8374 for details.4
Commercially Insured — Generic
Teva Generic Sorafenib Copay Card
$0 as low as, for eligible patients
Teva offers a copay assistance program for its generic sorafenib for eligible commercially insured patients. Not available for uninsured or government-insured patients. Our team can confirm which program applies to your prescription.6
Uninsured
Bayer US Patient Assistance Foundation
$0 for eligible uninsured patients
Brand Nexavar may be available at no cost for uninsured or underinsured patients who meet income guidelines. Applications require income documentation and are typically submitted with support from your oncologist's office.5
Medicare
Part D OOP Cap + Independent Foundations
$2,100 annual Part D maximum (2026)
The Nexavar copay card is not available for Medicare patients. Medicare Part D covers sorafenib at the specialty tier, with out-of-pocket costs capped at $2,100 per year as of 2026. Our team can help identify independent foundation programs that may provide additional support.4
Have questions about your specific coverage? Call 1-855-222-6730 or contact us online to discuss your options. Our team identifies what you qualify for and assists with enrollment.
Getting Started
What to Expect with Accord
Referral Sent
Your oncologist sends a referral to Accord by fax or online referral form.
Insurance Verified
We confirm your coverage, benefits, and any cost-sharing requirements.
Prior Authorization
We submit clinical documentation and manage the PA process on your behalf.
Financial Assistance
We identify programs that may fit your situation and help connect you to the right resources.
Doorstep Delivery
Your medication ships directly to your door in states where Accord is licensed.
Have Questions About Sorafenib?
Common Questions About Sorafenib (Nexavar)
Does Accord Specialty Pharmacy carry sorafenib (Nexavar)?
Yes. Accord is a licensed specialty pharmacy that dispenses both brand Nexavar and generic sorafenib. We manage prior authorization, copay card enrollment, financial assistance coordination, and doorstep delivery in states where Accord holds an active pharmacy license.
How do I transfer my sorafenib prescription to Accord?
Your oncologist can send a referral directly to Accord using our referral form, or by faxing to 386-456-3000. You can also call us at 1-855-222-6730 and our team will walk you through the process.
How does the Nexavar copay card work?
The Nexavar copay card is part of Bayer's Access Services program for eligible commercially insured patients. When enrolled, the program covers your out-of-pocket copay or coinsurance costs up to $25,000 per year, with no monthly maximum — meaning eligible patients may pay $0 per fill.4 The program is not available for Medicare, Medicaid, TRICARE, or other government-insured patients. Our team can help confirm your eligibility and assist with enrollment.
Is there a generic version of Nexavar?
Yes. Generic sorafenib is FDA-approved and available through specialty pharmacies. It contains the same active ingredient as brand Nexavar and must meet FDA bioequivalence standards.6 Teva's generic sorafenib also has its own copay assistance program for eligible commercially insured patients. Call us at 1-855-222-6730 to discuss which option makes sense for your coverage.
What is Nexavar patient assistance and do I qualify?
Nexavar patient assistance is available through the Bayer US Patient Assistance Foundation for uninsured or underinsured patients who meet income guidelines. If you qualify, the program provides Nexavar at no cost.5 Applications require income documentation and are typically supported by your oncologist's office. Call us at 1-855-222-6730 and our team can help determine whether you may be eligible.
How long does prior authorization take for sorafenib?
Timelines vary by insurance plan. Our team begins working on your prior authorization as soon as we receive your referral and follows up proactively. We keep both you and your oncologist updated throughout the process.
What if my insurance denies sorafenib?
A denial is not necessarily final. Our team works with your oncologist to submit a formal appeal with the additional clinical documentation needed to support your case. Many initially denied requests are approved on appeal.
Does sorafenib interact with blood thinners or other medications?
Yes. Taking sorafenib together with warfarin may increase the risk of bleeding or affect INR test results, so patients on warfarin are monitored closely. Sorafenib can also interact with certain other medications, including strong CYP3A4 inducers. Tell your oncologist and our pharmacy team about every medication, supplement, and over-the-counter product you take before starting sorafenib, and any time a new medication is added.
What should I do if I miss a dose of sorafenib?
If you miss a dose, take it as soon as you remember unless it is almost time for your next dose, in which case skip the missed dose and resume your regular schedule. Do not take a double dose to make up for a missed one. If you are unsure what to do, call our pharmacists at 1-855-222-6730 or check with your oncologist.
For Patients
Ready to Get Started?
Our team coordinates everything — insurance verification, prior authorization, copay card enrollment, and delivery. Call us or ask your oncologist to send a referral, and we take it from there.
Call 1-855-222-6730For Oncologists & Prescribers
Refer a Patient to Accord
Download the sorafenib referral form, complete all sections, and fax to 386-456-3000. We confirm receipt within one business day and manage prior authorization on your behalf.
Download Referral FormReferences (6)
- National Cancer Institute. Liver (Hepatocellular) Cancer Treatment (PDQ) — Patient Version. National Institutes of Health. cancer.gov
- Nexavar (sorafenib) Prescribing Information. Bayer HealthCare Pharmaceuticals Inc. U.S. Food and Drug Administration. accessdata.fda.gov
- National Cancer Institute. Renal Cell Cancer Treatment (PDQ) — Patient Version. National Institutes of Health. cancer.gov
- Bayer Access Services. Nexavar Co-Pay Program. patientassistance.bayer.us
- Bayer US Patient Assistance Foundation. Patient Assistance Program. patientassistance.bayer.us
- Drugs.com. Generic Nexavar (sorafenib) Availability. drugs.com